BACKGROUND: The optimal timing for nucleic acid amplification testing (NAAT) posttreatment for Trichomonas vaginalis has not been fully established. Testing too soon posttreatment may detect remnant nucleic acid that is not from viable organisms, falsely misclassifying person as infected. The purpose of this study was to examine how long T. vaginalis nucleic acid is detectable postmetronidazole (MTZ) treatment. METHODS: Women diagnosed with T. vaginalis treated with MTZ (2 g single-dose or 500 mg twice daily for 7 days multidose) self-collected a vaginal swab for NAAT at baseline and each week postcompletion of treatment through test of cure (TOC) at week 4, when a culture was also performed. Women who reported interim sexual exposure or who were culture positive at 4 weeks were excluded. Time to first negative NAAT was examined using Kaplan Meier analysis. RESULTS: All women receiving multidose metronidazole were NAAT-negative by 21 days and those receiving single dose by 28 days postcompletion of treatment. Though over half (60.7%) of the cohort reinitiated sex during follow-up¸ all reported using condoms during sex or that they and their partner were treated before sex. Six (6.7%) of 89 had a positive NAAT following their first negative NAAT. CONCLUSIONS: The optimal timing for T. vaginalis retesting after completion of treatment is 3 weeks for those receiving multidose MTZ and 4 weeks for those receiving single-dose, though sexual reexposure and false negatives should be considered.
BACKGROUND: The optimal timing for nucleic acid amplification testing (NAAT) posttreatment for Trichomonas vaginalis has not been fully established. Testing too soon posttreatment may detect remnant nucleic acid that is not from viable organisms, falsely misclassifying person as infected. The purpose of this study was to examine how long T. vaginalis nucleic acid is detectable postmetronidazole (MTZ) treatment. METHODS:Women diagnosed with T. vaginalis treated with MTZ (2 g single-dose or 500 mg twice daily for 7 days multidose) self-collected a vaginal swab for NAAT at baseline and each week postcompletion of treatment through test of cure (TOC) at week 4, when a culture was also performed. Women who reported interim sexual exposure or who were culture positive at 4 weeks were excluded. Time to first negative NAAT was examined using Kaplan Meier analysis. RESULTS: All women receiving multidose metronidazole were NAAT-negative by 21 days and those receiving single dose by 28 days postcompletion of treatment. Though over half (60.7%) of the cohort reinitiated sex during follow-up¸ all reported using condoms during sex or that they and their partner were treated before sex. Six (6.7%) of 89 had a positive NAAT following their first negative NAAT. CONCLUSIONS: The optimal timing for T. vaginalis retesting after completion of treatment is 3 weeks for those receiving multidose MTZ and 4 weeks for those receiving single-dose, though sexual reexposure and false negatives should be considered.
Authors: Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin Journal: J Acquir Immune Defic Syndr Date: 2010-12-15 Impact factor: 3.731
Authors: Thomas A Peterman; Lin H Tian; Carol A Metcalf; C Kevin Malotte; Sindy M Paul; John M Douglas Journal: Clin Infect Dis Date: 2009-01-15 Impact factor: 9.079
Authors: Jane R Schwebke; Marcia M Hobbs; Stephanie N Taylor; Arlene C Sena; Michael G Catania; Barbara S Weinbaum; Ann D Johnson; Damon K Getman; Charlotte A Gaydos Journal: J Clin Microbiol Date: 2011-09-21 Impact factor: 5.948
Authors: Barbara Van Der Pol; James A Williams; Stephanie N Taylor; Catherine L Cammarata; Charles A Rivers; Barbara A Body; Melinda Nye; Deanna Fuller; Jane R Schwebke; Mathilda Barnes; Charlotte A Gaydos Journal: J Clin Microbiol Date: 2014-01-03 Impact factor: 5.948
Authors: R Scott McClelland; Laura Sangare; Wisal M Hassan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Jeckoniah Ndinya-Achola; Walter Jaoko; Jared M Baeten Journal: J Infect Dis Date: 2007-01-22 Impact factor: 5.226
Authors: Charlotte A Gaydos; Marcia Hobbs; Jeanne Marrazzo; Jane Schwebke; Jenell S Coleman; Billie Masek; Laura Dize; Dan Jang; Jenny Li; Max Chernesky Journal: Sex Transm Dis Date: 2016-06 Impact factor: 2.830
Authors: Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny Journal: Clin Infect Dis Date: 2022-04-13 Impact factor: 20.999
Authors: Jane R Schwebke; Stephanie N Taylor; Ronald Ackerman; Robert Schlaberg; Neil B Quigley; Charlotte A Gaydos; Steven E Chavoustie; Paul Nyirjesy; Carmelle V Remillard; Philip Estes; Byron McKinney; Damon K Getman; Craig Clark Journal: J Clin Microbiol Date: 2020-01-28 Impact factor: 5.948
Authors: Christina A Muzny; Jane R Schwebke; Paul Nyirjesy; Gregory Kaufman; Leandro A Mena; Gweneth B Lazenby; Olivia T Van Gerwen; Keonte J Graves; Janeen Arbuckle; Belvia A Carter; Connette P McMahon; Scott Eder; Jackie Shaw; Brajesh Pandey; Steven E Chavoustie Journal: Clin Infect Dis Date: 2021-09-15 Impact factor: 9.079